Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06473779 · ClinicalTrials.gov registry record · Phase 3

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

A Phase 3 study of Severe Asthma, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
326
Enrollment target
20
Study locations

NCT06473779 is a Phase 3 study of Severe Asthma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 326 participants, below the 3,819-participant average among 9 other Severe Asthma trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06473779, a Phase 3 study of Severe Asthma, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
326 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).

Conditions Studied

Severe Asthma

Interventions

  • COMBINATION_PRODUCT Tezepelumab
  • COMBINATION_PRODUCT Budesonide/formoterol
  • COMBINATION_PRODUCT Albuterol/budesonide (AIRSUPRA®)
  • COMBINATION_PRODUCT Mannitol
  • COMBINATION_PRODUCT Salbutamol

Study Locations (20)

Other

  • Research Site - Berazategui
  • Research Site - CABA
  • Research Site - Concepción del Uruguay
  • Research Site - Mendoza
  • Research Site - Mendoza
  • Research Site - Quilmes
  • Research Site - Rosario
  • Research Site - Rosario
  • Research Site - San Miguel de Tucumán
  • Research Site - Santa Fe
  • Research Site - Anderlecht
  • Research Site - Edegem

California

  • Research Site - Palmdale

Colorado

  • Research Site - Colorado Springs

Florida

  • Research Site - Miami

Massachusetts

  • Research Site - Boston

Missouri

  • Research Site - St Louis

New Jersey

  • Research Site - New Brunswick

Oklahoma

  • Research Site - Oklahoma City

Trial Details

FieldValue
Enrollment Target 326 participants
Start Date 2024-09-30
Est. Completion 2027-06-25
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06473779

The ClinicalTrials.gov registry entry for NCT06473779 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,819-participant average among 9 other Severe Asthma trials with a reported enrollment target (91% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 5 interventions - of which Tezepelumab is the first listed.

NCT06473779 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06473779 about?

NCT06473779 is a clinical study titled "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.". The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. T...

What is the current status of trial NCT06473779?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2024-09-30. Estimated completion is 2027-06-25.

What conditions does trial NCT06473779 study?

This clinical trial studies the following conditions: Severe Asthma.

What interventions are being tested in trial NCT06473779?

The interventions under investigation include: Tezepelumab (COMBINATION_PRODUCT), Budesonide/formoterol (COMBINATION_PRODUCT), Albuterol/budesonide (AIRSUPRA®) (COMBINATION_PRODUCT), Mannitol (COMBINATION_PRODUCT), Salbutamol (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06473779?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06473779 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.